Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period" ...
bovnews7d
What’s Behind the 4.24% Gain in Humacyte Inc (HUMA) Stock? Find Out Now!
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 19.40% ...
Morningstar7d
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
Humacyte, Inc. (HUMA) Securities Class Action: The lawsuit claims that Humacyte and certain of its executives failed to disclose material adverse facts about the company’s business, operations ...
Business Wire10d
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Act…
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...
bovnews11d
What’s Causing Humacyte Inc (HUMA) Stock’s -40.24% Drop Over the Last Six Months?
On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...
Yahoo Finance3d
Humacyte, Inc. (HUMA)
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Buy” by Brokerages
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...
Stockhouse4d
Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
The Business Journals23d
Shareholder lawsuit shines light on biotech's FDA woes
Shareholders accuse Humacyte of misleading investors about quality issues. STORY HIGHLIGHTS Shareholders accuse Humacyte of misleading investors about quality issues. Humacyte's stock fell after ...
Nasdaq15d
Humacyte (HUMA) Insiders Show Confidence Despite Stock Decline
Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon ...
Morningstar28d
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...